The Lamkin Clinic, an Oklahoma-based provider of integrative, long-term healthcare solutions rooted in functional medicine, announced on Friday that those seeking help with depression or anxiety in Oklahoma can now benefit from a new, FDA-cleared, medication-free procedure.
According to the clinic, it is one of the first in Oklahoma to offer EXOMIND, a non-invasive brain stimulation treatment that is claimed to enhance mental wellness. With EXOMIND, an applicator delivers gentle magnetic pulses to stimulate or suppress brain activity, targeting areas involved in emotional regulation, cognitive function, and self-control. It is claimed that patients frequently report improved sleep quality, higher energy levels and enhanced emotional resilience. Clinical studies have also shown additional benefits such as reduced food cravings and an average weight loss after six treatments.
In addition, The Lamkin Clinic offers advanced therapies designed to support whole-body health and recovery such as growth hormone therapies, biotoxin illness, medical weight loss, thyroid optimization, platelet rich plasma therapy, incontinence, and many more.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval